Top

Published in:

01-12-2012 | Research Article

Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer

Authors: Yu-Jing Fang, Lin Zhang, Xiao-Jun Wu, Zhen-Hai Lu, Ji-Bin Li, Qing-Jian Ou, Mei-Fang Zhang, Pei-Rong Ding, Zhi-Zhong Pan, De-Sen Wan

Published in: Tumor Biology | Issue 6/2012

Abstract

The correlation of ERβ/CD44 expression and progression of patients with stage II of colon cancer were explored in this work. A total of 220 paraffin-embedded specimens with stage II colon cancer from 1995 to 2003 were included for assessing ERβ and CD44 by immunohistochemistry in normal mucosa and tumor tissues. Kaplen–Meier method, log–rank test, and the Cox proportional hazards regression model were used to analyze the overall survival data. ROC curve was used to describe the capacity of variables in prognosis prediction. Jackknife method was used to perform cross validation of predictions. The survival rates were significantly different between the patients with high expression and low expression of CD44-tumor tissues (61 % vs. 90 %, p < 0.0001) and between the patients with high expression and low expression of ERβ-tumor tissue (99 % vs. 36 %, p < 0.0001), respectively. In addition, the interaction between expression of ERβ and CD44 was found that the impact of CD44 to the overall survive appeared only when expression of ERβ was low; and the high expression of ERβ-tumor could be regarded as a protective factor for overall survival. This study suggest that low expression of ERβ-tumor and high expression of CD44-tumor are risk factors for overall survival in patients with stage II colon cancer.

Zheng S, Shanrong C. Colorectal cancer epidemiology and prevention study in China. Chinese-German J Clin Oncol. 2003;2:72–5.CrossRef

Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res. 2009;2:52–9.CrossRef

Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 2000;60:245–8.PubMed

Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER beta isoforms in colon cancer. Cancer Res. 2001;61:632–40.PubMed

Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ER beta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251–8.PubMedCrossRef

Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol. 2010;31:651–8.PubMedCrossRef

Cichy J, Pure E. The liberation of CD44. J Cell Biol. 2003;161:839–43.PubMedCrossRef

Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Hauβmann I, et al. A new variant of glycoprotein CD44 Confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.PubMedCrossRef

Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1303–13.PubMedCrossRef

10.

Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160:441–7.PubMedCrossRef

11.

Bai ZL, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm. 2009;324:133–49.CrossRef

12.

Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, et al. Survival versus apoptotic 17 beta-estradiol effect: role of ER alpha and ER beta activated non-genornic signaling. J Cell Physiol. 2005;203:193–201.PubMedCrossRef

13.

Galluzzo P, Caiazza F, Moreno S, Marino M. Role of ER beta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr-Relat Cancer. 2007;14:153–67.PubMedCrossRef

14.

Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep. 2005;14:17–21.PubMed

15.

Warner M, Gustafsson JA. The role of estrogen receptor beta (ER beta) in malignant diseases—a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun. 2010;396:63–6.PubMedCrossRef

16.

Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther. 2011;89:44–55.PubMedCrossRef

17.

Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini-Rew Med Chem. 2010;10:359–71.CrossRef

18.

Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Brit J Cancer. 2010;103:382–90.PubMedCrossRef

19.

Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012;147:18–24.PubMedCrossRef

20.

Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1994;344:1470–2.PubMedCrossRef

21.

Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993;177:443–55.PubMedCrossRef

22.

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion-migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744–9.PubMedCrossRef

23.

Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, et al. Tissue-specific promoters active in CD44(+)CD24(-/low) breast cancer cells. Cancer Res. 2008;68:5533–9.PubMedCrossRef

24.

Masson D, Denis MG, Denis M, Blanchard D, Loirat MJ, Cassagnau E, et al. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Brit J Cancer. 1999;80:1995–2000.PubMedCrossRef

25.

Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008;14:181–7.PubMedCrossRef

26.

Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog. 2007;46:1–14.PubMedCrossRef

27.

Nagano O, Murakami D, Hartmann D, de Strooper B, Saftig P, Iwatsubo T, et al. Cell-matrix interaction via CD44 is independently regulated by different metal loproteinases activated in response to extracellular Ca2+ influx and PKC activation. J Cell Biol. 2004;165:893–902.PubMedCrossRef

28.

Okamoto I, Kawano Y, Matsumoto M, Suga M, Kaibuchi K, Ando M, et al. Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins. J Biol Chem. 1999;274:25525–34.

29.

Kawano Y, Okamoto I, Murakami D, Itoh H, Yoshida M, Ueda S, et al. Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins. J Biol Chem. 2000;275:29628–35.PubMedCrossRef

30.

Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893–904.PubMedCrossRef

31.

Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002;21:3949–59.PubMedCrossRef

Title: Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer
Authors: Yu-Jing Fang
Lin Zhang
Xiao-Jun Wu
Zhen-Hai Lu
Ji-Bin Li
Qing-Jian Ou
Mei-Fang Zhang
Pei-Rong Ding
Zhi-Zhong Pan
De-Sen Wan
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0451-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma

Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients

Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma

Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen

CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer